Healthcare resource utilization and associated cost in patients with metastatic non-small cell lung cancer treated in the immunotherapy era
The treatment of mNSCLC carries a high economic burden, primarily driven by first-line therapy, especially with targeted and immune therapies. Further studies are needed to evaluate the impact of innovative treatments on the disease management costs of mNSCLC.
Authors
- Lior Apter (ORCID: https://orcid.org/0009-0005-9557-4270)
- Sivan Gazit (ORCID: https://orcid.org/0000-0001-9875-3550)
- Sarah Sharman Moser (ORCID: https://orcid.org/0000-0002-9745-2016)
- Nava Siegelmann‐Danieli (ORCID: https://orcid.org/0000-0001-7580-540X)
- Moshe Hoshen (ORCID: https://orcid.org/0000-0002-3107-5828)
- Dan Greenberg (ORCID: https://orcid.org/0000-0002-6759-3985)
- Gabriel Chodick (ORCID: https://orcid.org/0000-0002-5189-8995)
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Maccabi Institute for Health Services Research (IL)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1093/oncolo/oyae240
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57